The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: Effects of L-DOPA and the D1 agonist SKF 82958

Behavioural Pharmacology

Volumn 10, Issue 2, 1999, Pages 175-182

  Andringa, G ^a,b   Lubbers, L ^b   Drukarch, B ^a   Stoof, J C ^a   Cools, A R ^b,c  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; D1 agonist; Dyskinesia; L DOPA; MPTP; Parkinsonism; Primate; SKF 82958

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSKINESIA; DYSTONIA; EPILEPSY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PARKINSON DISEASE; RHESUS MONKEY;

EID: 0033034462     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199903000-00006     Document Type: Article

References (22)

1. Akai T, Ozawa M, Yamaguchi M, Mizuta E, Kuno S (1995). Behavioural involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP)-lesioned parkinsonian monkeys. Jap J Pharmacol 67:117-124.
2. Andringa G, Vermeulen RJ, Drukarch B, Renier WO, Stoof JC, Cools AR. (1999). The validity of the pre-treated, unilaterally MPTP-treated monkey as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81927. Behav Pharmacol 10:163-173.
3. Blanchet PJ, Bedard PJ, Britton DR, Kebabian JW (1993). Differential effects of selective D1 and D2 dopamine receptor agonists on L-DOPA induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 267:275-279.
4. Blanchet PJ, Grondin R, Bedard PJ, Shiosaki K, Britton DR (1996). Dopamine D1 receptor desensitisation in MPTP lesioned primates. Eur J Pharmacol 309:113-120.
5. DeNinno MP, Schoenleher R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JK, Ackerman M, Artman L, Bednarz L, et al. (1991). A-68930: a potent agonist selective for the dopamine D1 receptor. Eur J Pharmacol 199:209-219.
6. Domino EF (1997a). Selective full dopamine D1 like (SKF 82958) and D2 like (N 0923) agonist combination in the MPTP monkey model of hemiparkinsonism. Brain Res Bull 43(1):93-95.
7. Domino EF (1997b). Talipexole and pramipexole combinations with chloro APB (SKF 82958) in MPTP induced hemiparkinsonian monkeys. Eur J Pharmacol 325(2-3):137-144.
8. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD (1995a). Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology 117:275-286.
9. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD (1995b). The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology 117:287-297.
10. Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T (1996). Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res 719:129-137.
11. Guttman M, Fibiger HC, Jakubovic A, Calne DB (1990). Intracarotid 1-methyl-4-Phenyl-1,2,3,6-tetrahydropyridine administration: Biochemical and behavioural observations in a primate model of hemiparkinsonism. J Neurochem 54:1329-1334.
12. Johnson BJ, Peacock V, Schneider JS (1995). Dihydrexine, a full dopamine D1 receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys. Pharmacol Biochem Behav 51(4):617-622.
13. Kebabian JW, Britton DR, DeNinno MP, Ferner R, Smith L, Jenner P, Schoenleber R, Williams R (1990). A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203-209.
14. Kuno S (1997). Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP induced parkinsonian monkeys: clinical implications. Eur Neurol 38(suppl):18-22.
15. Löschmann PA, Smith LA, Lange KW, Jähnig P, Jenner P, Marsden CD (1992). Motor activity following the administration of selective D1 and D2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 109:49-56.
16. Nomoto M, Jenner P, Marsden CD (1988). The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset. Neurosci Lett 93:275-280.
17. Rouillard C, Bedard PJ, Di Paolo T (1990). Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. Eur J Pharmacol 185:209-215.
18. Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, et al. (1996). ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J Pharmacol Exp Ther 276(1):150-160.
19. Smith RD, Zhang Z, Kurlan R, McDermott M, Gash DM (1993). Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52(1):7-16.
20. Starr MS, Starr BS (1993). Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J Neural Transm (PD section) 6:27-34.
21. Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB (1993). Dopamine D1 receptors: efficacy of full (dihydrexine) and partial (SKF 383-93) agonists in primates vs rodents. Eur J Pharmacol 242:165-172.
22. Wolters EC, Vermeulen RJ, Goosen C, Stoof JC (1991). The unilateral MPTP lesioned monkey as an animal model of Parkinson" disease. In: Methods in Neuroscience Lesion and Transplantation.Conn PM (editor). San Diego: Academic Press. pp. 153-167.